Antimetabolites in Combination with Other Drugs Improve Therapy of Diffuse Aggressive Non-Hodgkin's Lymphoma

References

• DeVita V T, Jr, Canellos G P, Chabner B, et al. Advanced diffuse histiocytic lymphoma, a potentially curable disease: Results with combination chemotherapy. Lancet 1975; 1: 248–250
   PubMed Web of Science ®Google Scholar
• Jones S E, Fuks Z, Bull M, et al. Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation of 405 cases. Cancer 1973; 31: 806–823
   PubMed Web of Science ®Google Scholar
• Mackintosh F R, Colby T V, Podolsky W J, et al. Central nervous system involvement in non-Hodgkin's lymphoma: An analysis of 105 cases. Cancer 1982; 49: 586–595
   PubMed Web of Science ®Google Scholar
• Litman J P, Cabanillas F, Smith T L, et al. Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis. Blood 1979; 54: 1249–1257
   PubMed Web of Science ®Google Scholar
• Bunn P A, Schein P S, Banks P M, et al. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited. Blood 1976; 47: 3–10
   PubMed Web of Science ®Google Scholar
• Young R C, Howser D M, Anderson T, et al. Central nervous system complications of non-Hodgkin's lymphoma: The potential role for prophylactic therapy. Am J Med 1979; 66: 435–444
   PubMed Web of Science ®Google Scholar
• Cossman J, Jaffe E S, Fisher R I. Immunologic phenotypes of diffuse, aggressive non-Hodgkin's lymphomas. Correlation with clinical features. Cancer 1984; 54: 1310–1317
   PubMed Web of Science ®Google Scholar
• Cossman J, Chused T, Fisher R, et al. Diversity of immunologic phenotypes of lymphoblastic lymphoma. Cancer Res 1983; 43: 4486–4480
   PubMed Web of Science ®Google Scholar
• Lukes R J, Collins R D. New approaches to classification of the lymphomata. Br J Cancer 1975; 31: 1–27
   PubMed Web of Science ®Google Scholar
• Newcomer L N, Nerenberg M I, Cadman E C, et al. The usefulness of the Lukes-Collins Classification in identifying subsets of diffuse histiocytic lymphoma response to chemotherapy. Cancer 1982; 50: 439–443
   PubMed Web of Science ®Google Scholar
• Sweet D L, Collins R D, Stein R S, et al. Prognostic significance of the Lukes and Collins Classification in patients treated with COMLA. Cancer Treat Rep May 1982; 66(5)1107–1111
   PubMedGoogle Scholar
• Frei E, III, Schabel F, Jr, Goldin A. Comparative chemotherapy of AKR lymphoma and human hematologic neoplasia. Cancer Res 1974; 34: 184–193
   PubMed Web of Science ®Google Scholar
• Frei E, III, Spurr C L, Brindley C O, et al. Clinical studies of dichloro-methotrexate (NSC 29630). Clin Pharmacol Therap 1965; 6: 160–171
   PubMedGoogle Scholar
• Frei E, III, Schlossman S, Israel M. New approaches to the treatment of non-Hodgkin's lymphoma. Cancer Treat Rep 1977; 61: 1209–1217
   PubMedGoogle Scholar
• Livingstone R B, Carter S K. Single Agents in Cancer Chemotherapy. IGI/Plenum, New York 1970; 145
   Google Scholar
• Bertino J R. Clinical pharmacology of methotrexate. Med Pediatr Oncol 1982; 10: 401–411
   PubMedGoogle Scholar
• Frei E, III, Jaffe N, Tattersall M HN, et al. New approaches to cancer therapy with methotrexate. N Engl J Med 1975; 292: 846–851
   PubMed Web of Science ®Google Scholar
• Pitman S W, Parker L M, Tattersall M HN, et al. Clinical trial of high dose methotrexate (NSC-740) with citrovorum factor (NSC-3590)—toxicology and therapeutic observations. Cancer Chemother Rep 1975; 6(1)43–49, Part. 3
   Google Scholar
• Shapiro W, Young D, Mehta B. Methotrexate: Distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975; 293: 161–166
   PubMed Web of Science ®Google Scholar
• Frei E, III, Bickers J N, Hewlett J S, et al. Dose schedule and anti-tumor studies of arabinosyl cytosine. Cancer Res 1969; 29: 1325–1332
   PubMed Web of Science ®Google Scholar
• Kremer W B. Cytarabine. Ann Intern Med 1975; 82: 684–688
   PubMed Web of Science ®Google Scholar
• Monparler R L. A model for the chemotherapy of acute leukemia with 1-ß-D-arabinofuransylcytosine. Cancer Res 1979; 39: 42–49
   PubMedGoogle Scholar
• Capizzi R L, Yang J-L, Rathwell J P, et al. Dose-related pharmacologic effects of high dose Ara-C and its self-potentiation. Sem Oncol 1985; 12(Suppl)65–74
   PubMedGoogle Scholar
• Slevin M L, Piall E M, Aherne G W, et al. Effect of dose and schedule on pharmacokinetics of high dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1983; 1(9)546–551
   PubMed Web of Science ®Google Scholar
• Frei E, III, Canellos G P. Dose: A critical factor in cancer chemotherapy. Am J Med 1980; 69: 585–594
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Barlogie B, Plunkett W, et al. High dose cytosine arabinoside in non-Hodgkin's lymphoma. J Clin Oncol 1983; 1(11)689–694
   PubMed Web of Science ®Google Scholar
• Richards M A, Barnett M J, Waxman J H, et al. The use of high dose cytosine arabinoside for non-Hodgkin's lymphoma. Sem Oncol 1985; 12(Suppl)223–226
   PubMedGoogle Scholar
• Hoovis M L, Chu M Y. Enhancement of antiproliferative action of 1-ß arabinofuranosyl cytosine by methotrexate in murine leukemia cells (L5178Y). Cancer Res 1973; 33: 521–525
   PubMed Web of Science ®Google Scholar
• Edelstein M, Vietti T, Valeriote F. The enhanced cytotoxicity of combination of 1-ß-D arabinofuranosyl cytosine and methotrexate. Cancer Res 1975; 35: 1555–1558
   PubMed Web of Science ®Google Scholar
• Levitt M, Marsh J C, DeConti R C, et al. Combination sequential chemotherapy in advanced reticulum cell sarcoma. Cancer 1972; 29: 630–636
   PubMed Web of Science ®Google Scholar
• Berd D, Cornog J, DeConti R C, et al. Long term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy. Cancer 1975; 35: 1050–1054
   PubMed Web of Science ®Google Scholar
• Magrath I T, Janus C, Edwards B K. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 1984; 63: 1102–1111
   PubMed Web of Science ®Google Scholar
• Sabbah R, King M D. Improved survival of children with diffuse, undifferentiated lymphoma (DUL) with high dose methotrexate (HDM) and citrovorum factor (CF) rescue. Proc Am Assoc Cancer Res 1981; 22: 399
   Web of Science ®Google Scholar
• Sullivan M P, Ramivez I. Curability of Burkitt's lymphoma with high dose cyclophosphamide, high dose methotrexate therapy and intrathecal chemoprophylaxis. J Clin Oncol 1985; 3: 627–636
   PubMed Web of Science ®Google Scholar
• Sweet D L, Golomb H M, Ultman J E, et al. Cyclophosphamide, vincristine, methotrexate with leucovorin rescue and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Intern Med 1980; 92: 785–790
   PubMed Web of Science ®Google Scholar
• Portlock C S, Rosenberg R A. Combination chemotherapy with cyclophosphamide, vincristine and prednisone in advanced non-Hodgkin's lymphoma. Cancer 1976; 37: 1275–1282
   PubMed Web of Science ®Google Scholar
• Adler S, Katsutaro S, Han T, et al. Multiple agent chemotherapy for advanced histiocytic lymphoma. Eur J Cancer 1976; 12: 395–403
   PubMed Web of Science ®Google Scholar
• Durant J R, Loeb V, Dorfman R, et al. BCNU, cyclophosphamide, vincristine and prednisone, a new therapeutic regimen for diffuse histiocytic lymphoma. Cancer 1975; 36: 1936–1944
   PubMed Web of Science ®Google Scholar
• Lauria F, Baccarani M, Francchini M, et al. Methotrexate, cyclophosphamide and vincristine for non-Hodgkin's lymphoma. Cancer Treat Rep 1978; 62: 1193–1197
   PubMedGoogle Scholar
• Jones S E, Gozer P N, Metz E N, et al. Superiority of adriamycin containing combination chemotherapy in the treatment of diffuse lymphoma. Cancer 1979; 43: 417–425
   PubMed Web of Science ®Google Scholar
• Monfardini S, Gabriele T, Delena M, et al. CVP versus adriamycin, bleomycin and prednisone (ABP) in Stage IV non-Hodgkin's lymphoma. Med Pediatr Oncol 1977; 3: 67–74
   PubMedGoogle Scholar
• Schein P S, DeVita V T, Hubbard S, et al. Bleomycin, adriamycin, cyclophosphamide, vincristine and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med 1976; 85: 417–422
   PubMed Web of Science ®Google Scholar
• Skarin A T, Rosenthal D S, Moloney W C, Frei E, III. Combination chemotherapy of advanced non-Hodgkin's lymphoma with bleomycin, adriamycin, cyclophosphamide vincristine and prednisone (BACOP). Blood 1977; 49: 759–770
   PubMed Web of Science ®Google Scholar
• Armitage J O, Fyfe M AE, Lewis J. Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J Clin Oncol 1984; 2(8)898–902
   PubMed Web of Science ®Google Scholar
• McKelvey E M, Gottlieb J A, Wilson H E, et al. Hydroxydaunorubicin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
   PubMed Web of Science ®Google Scholar
• Rodriquez V, Cabanillas F, Burgess M A, et al. Combination chemotherapy (CHOP-Bleo) in advanced non-Hodgkin's lymphoma. Blood 1977; 49: 325–333
   PubMed Web of Science ®Google Scholar
• Cadman E, Farber L, Berd D, et al. Combination chemotherapy for diffuse histiocytic lymphoma that includes antimetabolites. Cancer Treat Rep 1977; 61: 1109–1116
   PubMedGoogle Scholar
• Newcomer L N, Cadman E C, Nererberg M I, et al. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue and cytarabine (ACOMLA) with cyclophosphamide doxorubicin, vincristine, prednisone and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma. Cancer Treat Rep 1982; 66: 1279–1284
   PubMedGoogle Scholar
• Todd M, Cadman E, Spiro P, et al. A follow-up of a randomized study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma. J Clin Oncol 1984; 2: 986–993
   PubMed Web of Science ®Google Scholar
• Klimo T, Connors J M. MACOP-B chemotherapy for treatment of diffuse large cell lymphoma. Ann Intern Med 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Coleman C N, Cohen J R, Burke J S, et al. Lymphoblastic lymphoma in adults: Results of a pilot protocol. Blood 1985; 57: 679–684
   Google Scholar
• Laurence J, Coleman M, Allen S L, et al. Combination chemotherapy of advanced diffuse histiocytic lymphoma with six drug combinations. Ann Intern Med 1982; 97: 190–195
   PubMed Web of Science ®Google Scholar
• Fisher R I, DeVita V T, Hubbard S M, et al. Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of ProMace and MOPP chemotherapy. Ann Intern Med 1983; 98: 304–309
   PubMed Web of Science ®Google Scholar
• Fisher R I, Young R C, Lango D, DeVita V T. ProMace-MOPP combination chemotherapy for diffuse lymphomas. Sem Oncol 1985; 12: 29–32
   PubMed Web of Science ®Google Scholar
• Levme A M, Forman S J, Meyer P R, et al. Successful therapy of convoluted T-lymphoblastic lymphoma in the adult. Blood 1983; 61: 92–98
   PubMed Web of Science ®Google Scholar
• Skarin A T, Canellos G P, Rosenthal D S, et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1983; 1: 91–97
   PubMed Web of Science ®Google Scholar
• Weinstein H J, Cassady J R, Levey R. Long-term results of the APO protocol, (vincristine, doxorubicin and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol 1983; 1: 537–541
   PubMed Web of Science ®Google Scholar
• Amadori S, Guglielmi C, Anselmo A P, et al. Treatment of diffuse aggressive non-Hodgkin's lymphomas with intensive multi-drug regimen including high dose cytosine arabinoside (F-MACHOP). Sem Oncol 1985; 12(Suppl)218–222
   PubMedGoogle Scholar
• Fisher R I, DeVita V T, Hubbard S M, et al. Randomized trial of ProMace-MOPP vs ProMace-CytaBOM in previously untreated, advanced stage diffuse aggressive lymphomas. Proc ASCO 1984; 25: 242
   Google Scholar
• Glickman A S, Pajak T F, Gottlieb A, et al. Second malignant neoplasms in patients successfully treated for Hodgkin's disease: A cancer and leukemia group B study. Cancer Treat Rep 1982; 66: 1035–1044
   PubMedGoogle Scholar
• Pedersen-Bjergaard J, Larsen S O. Incidence of acute non-lymphocytic leukemia, pre-leukemia and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med 1982; 307: 965–971
   PubMed Web of Science ®Google Scholar
• Greene M H, Boice J D, Jr, Greer B E, et al. Acute non-lymphocytic leukemia after therapy with alkylating agents for ovarian cancer: A study of five randomized clinical trials. N Engl J Med 1982; 307: 1416–1421
   PubMed Web of Science ®Google Scholar
• Valagussa P, Santoro A, Bellani F, et al. Absence of treatment induced second neoplasms after ABVD in Hodgkin's disease. Blood 1982; 59: 488–494
   PubMed Web of Science ®Google Scholar
• Berk P D, Goldberg J D, Silverstein M N, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981; 304: 441–447
   PubMed Web of Science ®Google Scholar
• Greene M H, Young R C, Merrill J M, et al. Evidence of a treatment dose response in acute non-lymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res 1983; 63: 1891–1898
   Google Scholar
• MacDougall B K, Weinerman B H, Kernel S. Second malignancies in non-Hodgkin's lymphoma. Cancer 1981; 48: 1299–1301
   PubMed Web of Science ®Google Scholar
• Gomez C A, Aggarwal K K, Han T. Post therapeutic acute malignant myeloproliferative syndrome and acute non-lymphocytic leukemia in non-Hodgkin's lymphoma. Cancer 1982; 50: 2285–2288
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Ersboll J, Sorensen H M, et al. Risk of acute non-lymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Ann Intern Med 1985; 103: 195–200
   PubMed Web of Science ®Google Scholar
• Todd M B, Portlock C S, Farber L R, et al. Prognostic indicators in diffuse histiocytic lymphoma. Intern J Radiat Oncol, in press
   Google Scholar